V503 Vaccine + REPEVAX™ (Concomitant) + REPEVAX™ (Non-concomitant)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Papillomavirus Infections
Conditions
Papillomavirus Infections
Trial Timeline
Apr 22, 2010 → Jun 16, 2011
NCT ID
NCT01073293About V503 Vaccine + REPEVAX™ (Concomitant) + REPEVAX™ (Non-concomitant)
V503 Vaccine + REPEVAX™ (Concomitant) + REPEVAX™ (Non-concomitant) is a phase 3 stage product being developed by Merck for Papillomavirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01073293. Target conditions include Papillomavirus Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01073293 | Phase 3 | Completed |
Competing Products
20 competing products in Papillomavirus Infections